Aptamer Group has signed a research collaboration to develop delivery vehicles that target heart and skeletal muscle, extending the reach of its Optimer technology into a potentially large therapeutic market. Announced on 26 October 2026, the Partnership with Pharmahungary Group came shortly after the company reported full-year Revenue growth and said its cash was expected to fund operations into 2028.

What the company does

Aptamer Group is a UK-based biotechnology company that develops Optimer binders, synthetic molecules that recognise and bind to specific targets in a similar way to antibodies. The company works with pharmaceutical, diagnostics and life science customers, earning fees for discovery and development work and, increasingly, seeking licensing income where its binders are built into partners' products. Applications range from therapeutic delivery and diagnostics to research tools.

Latest developments

Under the Pharmahungary agreement, each party will fund its own work and retain its own intellectual property. Aptamer will build and validate the targeting system and produce Optimer conjugates using Pharmahungary's microRNA, while Pharmahungary will fund preclinical studies. Aptamer said a comparable preclinical package would typically cost between £300,000 and £500,000, and that the deal involved no unbudgeted spending and did not change its cash runway. Aptamer will keep full ownership of its delivery vehicles and own 50% of the combined therapeutic. Chief executive Arron Tolley described it as progress against the goals set out at the time of the company's fundraising. If the research is successful, the two companies intend to seek licensing deals jointly with pharmaceutical partners.

Earlier in the year, Aptamer announced contract wins and its first cash licensing receipts in January, the use of its technology in a launched library preparation kit in February, a targeted radiopharmaceutical programme in March, a rapid testing programme for fortified foods in June and an Ebola diagnostic test programme in July.

Financial and Dividend picture

In full-year results published on 13 October 2026, covering the twelve months to 30 June 2026, Aptamer reported revenue up 28% to about £1.5 million. The adjusted EBITDA loss was about £2.3 million, and administrative expenses were around £3.2 million.

The company raised about £4.1 million through a placing, subscription and retail offer announced in March 2026, alongside its interim results, and held cash of about £4.4 million at the year end. It said this was expected to fund operations into calendar 2028. The sales pipeline had grown to about £7.0 million by September 2026, and the company is moving key pharmaceutical relationships onto multi-year master service agreements. It also reported new licensing agreements for enzyme-modulating Optimers. Aptamer does not pay a dividend.

Sector and index context

Aptamer is one of the smaller life sciences companies in the FTSE AIM All Share Index. The market for oligonucleotide therapeutics, which the Pharmahungary deal targets, has been forecast to reach US$17.7 billion by 2030, according to the figure cited in the announcement. Delivering such drugs to tissues beyond the liver remains a significant scientific challenge.

Key risks

The Business remains loss-making, and revenue is modest relative to costs. Converting pipeline into signed contracts and recurring licence income is uncertain, and preclinical collaborations may not lead to commercial licences. Further fundraising could be required if growth is slower than planned.

What to watch next

Investors will look for conversion of the £7.0 million pipeline, further licensing deals and early data from the Pharmahungary collaboration. Interim results for the six months to December 2026 are likely to be the next detailed financial update.